文献速递哮喘

哮喘中TRAIL及其受体在1型、2型和17型炎症中的作用

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and receptors in type 1, type 2 and type 17 inflammation in cross-sectional asthma study.
PubMed 文献 · Thorax · 2020-06-01

本研究基于严重哮喘研究计划,分析痰液、支气管肺泡灌洗液和活检中TRAIL及其受体的表达。高TRAIL组白细胞显著增加,并与1型、2型和17型细胞因子升高相关,TRAIL基因两个变异与痰TRAIL水平升高相关。痰白细胞上诱骗受体R3/DcR1高于死亡受体R1/DR4,提示凋亡减少和炎症持续。

要点

  • 高TRAIL与痰、BALF和活检中所有白细胞显著增加相关
  • 高TRAIL与1型、2型和17型细胞因子升高相关,但与IL-9无关
  • TRAIL基因两个变异与痰TRAIL水平升高相关

核心结论

  • 高TRAIL与哮喘患者气道白细胞增多及1型、2型和17型炎症相关。
  • TRAIL诱骗受体R3/DcR1在痰白细胞上表达高于死亡受体R1/DR4,提示凋亡减少和细胞炎症持续。

研究设计与样本

  • 横断面研究,纳入严重哮喘研究计划(Wake Forest)受试者。
  • 检测痰液、支气管肺泡灌洗液和活检中的TRAIL及细胞受体。

主要发现

  • 高TRAIL组所有白细胞显著增加。
  • 高TRAIL与1型、2型和17型细胞因子增加相关,但与9型白细胞介素9无关。
  • TRAIL基因两个位点变异与痰TRAIL水平升高相关。
  • 痰白细胞上诱骗受体R3/DcR1高于死亡受体R1/DR4。

临床怎么用

  • TRAIL及其受体可能作为哮喘炎症分型和治疗靶点的潜在标志物。

局限性

  • 横断面设计无法确定因果关系。
  • 样本来源限于严重哮喘研究计划的受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) reportedly promotes, or conversely, resolves inflammation in asthma. In this study of TRAIL and cell receptors in sputum, bronchoalveolar lavage and biopsy from subjects in the Severe Asthma Research Program at Wake Forest, the high TRAIL group had significant increases in all leucocytes, and was associated with increased type 1, type 2 and type 17 cytokines, but not type 9 interleukin 9. Two variants at loci in the TRAIL gene were associated with higher sputum levels of TRAIL. Increased TRAIL decoy receptor R3/DcR1 was observed on sputum leucocytes compared with death receptor R1/DR4, suggesting reduced apoptosis and prolonged cellular inflammation.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Marks M, Steele C, Moore WC, et al. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and receptors in type 1, type 2 and type 17 inflammation in cross-sectional asthma study. Thorax. 2020. PMID: 32482836. doi:10.1136/thoraxjnl-2019-214496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。